Drug manufacturer part of boost in research for GVHD

11/28/2007 | Rutland Herald (Vt.)

The FDA rejected a drug to treat graft-versus-host disease in bone marrow transplant patients, but now the drug's manufacturer says it will conduct additional research to satisfy FDA concerns. The manufacturer is part of a boost in research of the disease, which affects at least 50% of those who receive donated marrow or stem cell transplants in the U.S. each year.

View Full Article in:

Rutland Herald (Vt.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC